SCANDIUM-III
A PHASE III RANDOMIZED CONTROLLED MULTICENTRE TRIAL OF PERCUTANEOUS HEPATIC PERFUSION IN COMBINATION WITH IPILIMUMAB AND NIVOLUMAB COMPARED TO IPILIMUMAB AND NIVOLUMAB ONLY IN PATIENTS WITH UVEAL MELANOMA LIVER METASTASES
EU Trial number: 2023-508156-20-00 (approved 2024-04-21)
CIV-ID: CIV-23-12-045456
Sponsor
Sahlgrenska University Hospital, Gothenburg
National coordinator
Roger Olofsson Bagge
Lars Ny Sahlgrenska University Hospital, Gothenburg
Principal investigators and sites
Sara Wirén Norrlands University Hospital, Umeå
Hildur Helgadottir Karolinska University Hospital, Stockholm
Sander Ellegård Linköping University Hospital, Linköping
Gustav Ullenhag Uppsala University Hospital, Uppsala
Ana Carneiro Skåne University Hospital, Lund